• Explore /
  • Poster
  • / Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.

Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.

Abstract Poster

Authors

null

Anastasia Constantinidou

The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom

Anastasia Constantinidou , Yiola Marcou , Timothy Simmons , Ryan Bernhisel , Elisha Hughes , Stephanie Meek , Eleni I. Kakouri , Georgios Georgiou , Ioanna Zouvani , Gabriella Savvidou , Vanessa Kuhl , Jennifer Doedt , Susanne Wagner , Alexander Gutin , Jerry Lanchbury , Ralf Kronenwett , Emad A. Rakha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 537)

DOI

10.1200/JCO.2021.39.15_suppl.537

Abstract #

537

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Erika P. Hamilton

First Author: Seock-Ah Im

First Author: William John Gradishar

Poster

2024 ASCO Annual Meeting

Predicting epirubicin response in Danish patients with breast cancer.

Predicting epirubicin response in Danish patients with breast cancer.

First Author: Ida Kappel Buhl